FDA Advisory Committee Meetings
Public meetings where independent experts review a drug application and vote on its benefit–risk — a high-drama catalyst that usually foreshadows the FDA decision.
No Upcoming FDA Advisory Committee Meetings
There are no pending fda advisory committee meetings at this time.
About FDA Advisory Committee Meetings
An FDA Advisory Committee (AdCom) meeting convenes a panel of external experts — clinicians, statisticians, and often a patient representative — to publicly review a marketing application and vote on questions such as whether a drug’s benefits outweigh its risks.
The FDA is not bound by the panel’s vote, but it follows the recommendation in the large majority of cases. Briefing documents released ahead of the meeting, the live vote, and FDA staff reviews are each distinct, tradable moments.
Why AdCom Meetings matter to investors
AdComs are unusually information-dense: the FDA’s own briefing documents (published ~two days prior) often move the stock more than the vote itself, and a surprise negative panel can pre-empt a PDUFA rejection. They are among the most volatile scheduled biotech events.
Frequently asked questions
What is an FDA Advisory Committee (AdCom) meeting?
An AdCom is a public meeting where independent experts review a drug application and vote on its benefit–risk profile to advise the FDA. The FDA usually, but not always, follows the panel.
Does the FDA have to follow the AdCom vote?
No — the vote is advisory. Historically the FDA aligns with the committee in roughly three-quarters of cases, so a strong vote is a positive signal but not a guarantee.
Why do AdCom briefing documents move stocks?
The FDA publishes its own review briefing about two days before the meeting. Those documents reveal the agency’s concerns and frequently drive the largest price move of the event.